"PV"@en . . . . . "# : Inadvertent use of Bicillin C-R to treat syphilis infection--Los Angeles, California, 1999-2004. MMWR Morb Mortal Wkly Rep. 2005 Mar 11;54(9):217-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15758893 # Gruchalla RS, Pirmohamed M: Clinical practice. Antibiotic allergy. N Engl J Med. 2006 Feb 9;354(6):601-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16467547"@en . "Penicillin Phenoxymethyl"@en . . " "@en . . . "Borrelia burgdorferi"@en . . . "Phenoxomethylpenicillin"@en . . . . . "Absorption is increased when taken on an empty stomach (one hour before or two hours after meals)."@en . "Hephzibah Sivaraman, Archana Pundle, Cheravakkattu Suresh, George Dodson, James Brannigan, \"Process for production of large amount of penicillin V acylase.\" U.S. Patent US20050142652, issued June 30, 2005."@en . "Phenoxymethyl Penicillin"@en . . . . . "Phenoxymethylpenicillinum"@en . . . . . . . "30 to 40 minutes"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Gram-negative Bacteria"@en . . . . . . . . . . . . . . . "Phenoxymethylenepenicillinic acid"@en . . . "(2S,5R,6R)-3,3-DIMETHYL-7-oxo-6-(2-phenoxyacetamido)-4-thia-1- azabicyclo(3.2.0)heptane-2-carboxylic acid"@en . . . . . . . . "Fenoximetilpenicilina"@en . "By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Penicillin V inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Penicillin V interferes with an autolysin inhibitor."@en . . . . . . . . "Fenospen"@en . . . "6-phenoxyacetamidopenicillanic acid"@en . . "Phenoxymethylpenicillin"@en . . . . . . . . . . . . . . . . . . . "(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"@en . . . . " "@en . . "Mostly renal. A small percentage is eliminated by feces and the biliary route."@en . "Penicillin v"@en . "80%"@en . "LD₅₀ >1040 mg/kg (Orally in rats with Sodium salt); Nausea, vomiting, stomach pain, diarrhea, and, in rare cases, major motor seizures"@en . "Streptococcus pyogenes"@en . "87-08-1"@en . . . . . "V-cillin"@en . . . . . "Bacteria"@en . . . "25% of the dose given is absorbed, 50-60% bioavailable"@en . . . "approved"@en . "Bacillus anthracis"@en . . "Penicillin V"@en . . "Penicillin V is narrow spectrum antibiotic used to treat mild to moderate infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered orally. Penicillin V may also be used in some cases as prophylaxis against susceptible organisms. Natural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as Streptococcus pneumoniae, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (S. agalactiae), S. viridans, and Enterococcus faecalis. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as Bacillus anthracis, Corynebacterium diphtheriae, and Erysipelothrix rhusiopathiae. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by Neisseria meningitidis and Pasteurella. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions. "@en . . "Oracillin"@en . . . "Phenoxymethylpenicilline"@en . . . . . . "For the treatment of mild to moderately severe infections (e.g. dental infection, infections in the heart, middle ear infections, rheumatic fever, scarlet fever, skin infections, upper and lower respiratory tract infections) due to microorganisms"@en . .